- |||||||||| TOL-463 / Toltec Pharma
Enrollment closed, Trial primary completion date: TOL-463 Phase 2 Study for Vaginitis (clinicaltrials.gov) - May 19, 2017 P2, N=106, Active, not recruiting, Trial primary completion date: Apr 2017 --> Apr 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jan 2017 --> Jun 2017
- |||||||||| Mifeprex (mifepristone) / Danco Laboratories
Enrollment closed, Enrollment change, Metastases: Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 12, 2017 P1, N=31, Active, not recruiting, No longer recruiting --> Completed Recruiting --> Active, not recruiting | N=22 --> 31
- |||||||||| topotecan / Generic mfg., acetylcysteine solution / Generic mfg.
Biomarker, Enrollment closed, Enrollment change, Trial primary completion date, Tumor microenvironment: Effect of Acetylcysteine With Topotecan Hydrochloride on the Tumor Microenvironment in Patients With Persistent or Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer (clinicaltrials.gov) - May 11, 2017 P2, N=1, Active, not recruiting, Phase classification: P=N/A --> P3 Recruiting --> Active, not recruiting | N=48 --> 1 | Trial primary completion date: Oct 2020 --> Oct 2019
- |||||||||| Preclinical, Trial primary completion date: Use of IMSI in Poor Responders to IVF (clinicaltrials.gov) - May 10, 2017
P=N/A, N=200, Recruiting, Trial primary completion date: Jan 2017 --> Jul 2017 Trial primary completion date: Jan 2017 --> Jan 2018
- |||||||||| clomifene citrate / Generic mfg.
Preclinical, Enrollment change, Trial withdrawal: IVF Versus LOD in Women With CC Resistant PCOS (clinicaltrials.gov) - May 10, 2017 P4, N=0, Withdrawn, N=100 --> 0 | Not yet recruiting --> Withdrawn N=100 --> 0 | Not yet recruiting --> Withdrawn
- |||||||||| lorazepam / Generic mfg., ibuprofen / Generic mfg.
Trial primary completion date: Analgesia for Endometrial Scratching (clinicaltrials.gov) - May 9, 2017 P=N/A, N=150, Enrolling by invitation, Active, not recruiting --> Completed Trial primary completion date: Mar 2017 --> Sep 2017
- |||||||||| Trial completion, Enrollment change, Trial primary completion date: EGEN-001 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer (clinicaltrials.gov) - May 8, 2017
P2, N=22, Completed, Recruiting --> Active, not recruiting Active, not recruiting --> Completed | N=56 --> 22 | Trial primary completion date: Dec 2017 --> Jul 2016
- |||||||||| metformin / Generic mfg.
Trial primary completion date: Metformin for the Treatment of Endometrial Hyperplasia (clinicaltrials.gov) - May 4, 2017 P, N=18, Active, not recruiting, Trial primary completion date: Dec 2017 --> Dec 2018 Trial primary completion date: Dec 2016 --> Dec 2015
- |||||||||| trebananib (AMG 386) / Amgen
Trial termination: AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) (clinicaltrials.gov) - May 4, 2017 P3, N=223, Terminated, Recruiting --> Completed Active, not recruiting --> Terminated; Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU.
- |||||||||| Trial completion, Enrollment change, Trial initiation date, Trial primary completion date: The Effect of a Coloring Prompt on Health Engagement (clinicaltrials.gov) - May 4, 2017
P=N/A, N=8711, Completed, Active, not recruiting --> Terminated; Closure of long term follow up (LTFU) and study earlier than previously outlined in the protocol as no beneficial information gained from continuing LTFU. Recruiting --> Completed | N=15000 --> 8711 | Initiation date: May 2014 --> May 2011 | Trial primary completion date: Dec 2016 --> Nov 2012
- |||||||||| trebananib (AMG 386) / Amgen
Trial completion, Enrollment change, Trial primary completion date: Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer (clinicaltrials.gov) - May 4, 2017 P2, N=35, Completed, Recruiting --> Completed | N=15000 --> 8711 | Initiation date: May 2014 --> May 2011 | Trial primary completion date: Dec 2016 --> Nov 2012 Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016
- |||||||||| Trial primary completion date: Yoga Practice for Breast or Ovarian Cancer Patients (clinicaltrials.gov) - May 3, 2017
P=N/A, N=39, Active, not recruiting, Active, not recruiting --> Completed | N=55 --> 35 | Trial primary completion date: Mar 2016 --> Jul 2016 Trial primary completion date: Nov 2017 --> Nov 2018
- |||||||||| clomifene citrate / Generic mfg.
Trial completion, Enrollment change: NAC in CC Resistant PCOS After LOD (clinicaltrials.gov) - May 2, 2017 P2/3, N=144, Completed, Initiation date: Feb 2017 --> Jun 2017 Recruiting --> Completed | N=120 --> 144
- |||||||||| Enrollment closed, Enrollment change, Trial primary completion date: Effect of Sorting of Apoptotic Spermatozoa on the Outcome of Assisted Reproduction (clinicaltrials.gov) - May 1, 2017
P=N/A, N=100, Active, not recruiting, Initiation date: Jul 2016 --> Jan 2018 | Not yet recruiting --> Suspended | Trial primary completion date: Nov 2017 --> Jan 2020 Recruiting --> Active, not recruiting | N=200 --> 100 | Trial primary completion date: Dec 2015 --> Jan 2017
|